

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INSIDE INFORMATION
EXCLUSIVE LICENSE AGREEMENT WITH CALDERA THERAPEUTICS
FOR THE DEVELOPMENT AND COMMERCIALIZATION OF QX030N

This announcement is made by Qyuns Therapeutics Co., Ltd. (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

INTRODUCTION

The Board is pleased to announce that on April 23, 2025, the Company and Caldera Therapeutics have entered into an out-license agreement (the “**License Agreement**”). The License Agreement grants Caldera Therapeutics an exclusive right to develop and commercialize QX030N globally.

PRINCIPAL TERMS OF THE LICENSE AGREEMENT

Subject to terms and conditions of the License Agreement, Caldera Therapeutics is granted an exclusive, royalty-bearing, transferable, sublicensable right to research, develop, register, manufacture and commercialize QX030N worldwide. In return, the Company or its designated affiliate(s) (collectively, the “**Group**”) will be entitled to receive a one-time, non-refundable, and non-creditable upfront payment of USD\$10 million, and to receive approximately 24.88% of the equity interest in Caldera Therapeutics. The Group may also receive additional payments of up to USD\$545 million, subject to the achievement of certain clinical development, regulatory and commercial milestones. The Group will also be entitled to receive tiered royalties on net sales from Caldera Therapeutics during a specified time period after the first commercial sales of QX030N.

In connection with the License Agreement, the Company and Caldera Therapeutics have also entered into a share purchase agreement on the same date of the License Agreement under which the Group agrees to acquire the mentioned equity interest in Caldera Therapeutics above.

ABOUT QX030N

QX030N is a long-acting bispecific antibody in the pre-clinical stage for the treatment of immunologic disorders.

ABOUT CALDERA THERAPEUTICS

Caldera Therapeutics is a company newly incorporated in the United States, for the primary purpose of drug development and commercialization, including development and commercialization of QX030N. Caldera Therapeutics was founded by leading biotech investors Lilly Asia Ventures, Atlas Venture, and venBio.

To the best knowledge and belief of the Company, the ultimate beneficial owners of Caldera Therapeutics and its shareholders are not connected person (as defined in the Listing Rules) of the Company. The transactions contemplated under the License Agreement do not constitute any notifiable transaction or connected transaction of the Company which are subject to announcement requirements under the Listing Rules.

BENEFITS OF THE LICENSE AGREEMENT

The Board believes that entering into the License Agreement will significantly contribute to the Company's business expansion in the biopharmaceutical sector and is in the best interests of the Company and the Shareholders as a whole. The Company will continue to further enhance its global cooperation network through its innovative technology platforms, thereby maximizing the Group's pipeline value and commercial value.

Warning: There is no assurance that the Company will ultimately develop, launch and/or commercialize QX030N successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

DEFINITIONS

"Board"	the board of Directors
"Caldera Therapeutics"	Caldera Therapeutics, Inc., a Delaware corporation with a business address at 300 Technology Square, 8th Floor, Cambridge, MA 02139, U.S.A.
"Company"	Qyuns Therapeutics Co., Ltd.
"Director(s)"	director(s) of the Company
"Group"	the Company together with its subsidiaries
"License Agreement"	the exclusive out-license agreement dated April 23, 2025 entered into among the Company and Caldera Therapeutics

“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“Shareholder(s)”	holder(s) of the Company’s share(s)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“USD”	United States dollar(s), the lawful currency of the United States
“%”	per cent

By order of the Board
Qyuns Therapeutics Co., Ltd.
Mr. Qiu Jiwan
Chairman of the Board and Executive Director

Hong Kong, April 24, 2025

As at the date of this announcement, the Board of the Company comprises Mr. Qiu Jiwan as chairman and executive Director, Mr. Wu Yiliang and Mr. Lin Weidong as executive Directors, Mr. Yu Xi and Mr. Wu Zhiqiang as non-executive Directors, and Dr. Zou Zhongmei, Dr. Ling Jianqun and Mr. Fung Che Wai, Anthony as independent non-executive Directors.